{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.938","upperLimit":"1.034","value":"0.985"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"We assessed PD-L1 expression using immunohistochemistry on pre-treatment tumor tissue. The outcome of measurement was complete response yes vs. no. Using logistic regression, we assessed if the percentage of PDL1+ cells was predictive of achieving a complete response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.","id":"OG000","title":"Nivo and EPOCH"}],"paramType":"NUMBER","populationDescription":"Only 17 participants had tumor tissue available.","reportingStatus":"POSTED","timeFrame":"Within 6 months of treatment","title":"Immune-related Predictors of Response","type":"SECONDARY","unitOfMeasure":"odds ratio"}